Patents by Inventor Zu Y. Cai

Zu Y. Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6359152
    Abstract: This invention provides a novel class of vitamin D compounds, namely, 13-ethyl and 13-vinyl-18,19-dinor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from the group consisting of an ethyl or vinyl radical, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 18-substituted compounds are characterized by minimal intestinal calcium transport activity and minimal bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of secondary hyperparathyroidism.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: March 19, 2002
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Zu Y. Cai
  • Publication number: 20010051617
    Abstract: This invention provides a novel class of vitamin D compounds, namely, 13-ethyl and 13-vinyl-18,19-dinor-vitamin D derivatives, as well as a general method for their chemical synthesis.
    Type: Application
    Filed: May 15, 2001
    Publication date: December 13, 2001
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Zu Y. Cai
  • Patent number: 6281249
    Abstract: This invention provides a novel class of vitamin D compounds, namely, 13-ethyl and 13-vinyl-18,19-dinor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from the group consisting of an ethyl or vinyl radical, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 18-substituted compounds are characterized by minimal intestinal calcium transport activity and minimal bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of secondary hyperparathyroidism.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: August 28, 2001
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Zu Y. Cai
  • Patent number: 5976784
    Abstract: A method of treating metabolic bone diseases such as osteoporosis, as well as other disease states treatable with vitamin D compounds, comprises administering an effective amount of one or more modified vitamin D compound. The modified compound contains a typical vitamin D nucleus but with in vivo hydrolyzable groups at one or more of the 1, 3 and 25 carbon positions. The time of conversion of the modified compound to its active form, such as calcitriol, can be regulated to thus provide controlled release of the compound in vivo over time, by changing or modifying the hydrolyzable groups.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 2, 1999
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Heinrich K. Schnoes, Zu Y. Cai, Mary E. Phelps, Connie M. Smith
  • Patent number: 5939406
    Abstract: This invention provides a novel class of vitamin D compounds, namely, 13-ethyl and 13-vinyl-18,19-dinor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: ##STR1## where Y.sub.1 and Y.sub.2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R.sub.6 is selected from the group consisting of an ethyl or vinyl radical, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 18-substituted compounds are characterized by minimal intestinal calcium transport activity and minimal bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of secondary hyperparathyroidism.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: August 17, 1999
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Zu Y. Cai